IDEAYA Biosciences (IDYA) Cash from Operations (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Cash from Operations of 75170000.0 for Q1 2026, up 16.94% sequentially from 90496000.0 in Q4 2025, and down 24.57% YoY from 99659624.29 in Q1 2025.
IDEAYA Biosciences (IDYA) Cash from Operations (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Cash from Operations for 9 years, with the latest figure at 75170000.0 in Q1 2026.
- Quarterly Cash from Operations fell 24.57% year-over-year to 75170000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85926000.0 (up 67.47% YoY) and the FY2025 annual result came in at 71098000.0, up 71.28% from the prior year.
- Cash from Operations improved to 75170000.0 in Q1 2026 per IDYA's latest filing, from 90496000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 142214000.0 in Q3 2025 and troughed at 121655000.0 in Q4 2024.
- A 5-year average of 35073588.24 and a median of 32882000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 412.27% in 2024, then soared 388.85% in 2025.
- Over 5 years, Cash from Operations stood at 23370000.0 in 2022, then dropped by 1.62% to 23748000.0 in 2023, then plunged by 412.27% to 121655000.0 in 2024, then climbed by 25.61% to 90496000.0 in 2025, then climbed by 16.94% to 75170000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 75170000.0, 90496000.0, and 142214000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -88.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.21 Mn |
| Jun 30, 2026 | -88.21 Mn |
| Mar 31, 2026 | -75.17 Mn |
| Mar 31, 2026 | -75.17 Mn |
| Dec 31, 2025 | -90.50 Mn |
| Dec 31, 2025 | -90.50 Mn |
| Sep 30, 2025 | 142.21 Mn |
| Sep 30, 2025 | 142.21 Mn |
| Jun 30, 2025 | -62.47 Mn |
| Jun 30, 2025 | -62.47 Mn |
| Mar 31, 2025 | -60.34 Mn |
| Mar 31, 2025 | -60.34 Mn |
| Dec 31, 2024 | -121.66 Mn |
| Dec 31, 2024 | -121.66 Mn |
| Sep 30, 2024 | -49.23 Mn |
| Sep 30, 2024 | -49.23 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Jun 30, 2024 | -32.88 Mn |
| Mar 31, 2024 | -43.81 Mn |
| Mar 31, 2024 | -43.81 Mn |